{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:48:35Z","timestamp":1791679715983,"version":"4.3.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"University of Southern Denmark","id":[{"id":"https:\/\/ror.org\/03yrrjy16","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"DOI":"10.1007\/s40263-026-01338-0","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:22:12Z","timestamp":1791667332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Parental Cardiometabolic History, Family Income, and Cardiometabolic Risk in Antipsychotic-Treated Children, Adolescents, and Young Adults: A Nationwide Cohort Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5786-5203","authenticated-orcid":false,"given":"Mikkel","family":"H\u00f8jlund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9700-2739","authenticated-orcid":false,"given":"Rikke","family":"Wesselhoeft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0818-8338","authenticated-orcid":false,"given":"Anne Katrine","family":"Pagsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6400-4436","authenticated-orcid":false,"given":"Hans-Christoph","family":"Steinhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"1338_CR1","unstructured":"American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of antipsychotic medications in children and adolescents. 2011. https:\/\/www.aacap.org\/App_Themes\/AACAP\/docs\/practice_parameters\/Atypical_antipsychotic_Medications_Web.pdf. Accessed 4 Oct 2025."},{"key":"1338_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1089\/cap.2018.0115","volume":"29","author":"MS Fallah","year":"2019","unstructured":"Fallah MS, Shaikh MR, Neupane B, Rusiecki D, Bennett TA, Beyene J. Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. J Child Adolesc Psychopharmacol. 2019;29:168\u201380. https:\/\/doi.org\/10.1089\/cap.2018.0115.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1338_CR3","unstructured":"Food and Drug Administration. Prescribing information: Abilify (aripiprazole). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021436s046s050lbl.pdf. Accessed 7 Aug 2026."},{"key":"1338_CR4","unstructured":"Food and Drug Administration. Prescribing information: Risperdal (risperidone). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/020272s088,020588s074,021444s060lbl.pdf. Accessed 7 Aug 2026."},{"key":"1338_CR5","unstructured":"Food and Drug Administration. Prescribing information: Latuda (lurasidone). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/200603s041lbl.pdf. Accessed 7 Aug 2026."},{"key":"1338_CR6","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1111\/bcp.15388","volume":"88","author":"M H\u00f8jlund","year":"2022","unstructured":"H\u00f8jlund M, Rasmussen L, Olesen M, Munk-Olsen T, Potteg\u00e5rd A. Who prescribes quetiapine in Denmark? Br J Clin Pharmacol. 2022;88:4224\u20139. https:\/\/doi.org\/10.1111\/bcp.15388.","journal-title":"Br J Clin Pharmacol"},{"key":"1338_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","volume":"28","author":"M Krause","year":"2018","unstructured":"Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol. 2018;28:659\u201374. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.03.008.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1338_CR8","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1017\/S1092852921000523","volume":"27","author":"P Singappuli","year":"2022","unstructured":"Singappuli P, Sonuga-Barke E, Kyriakopoulos M. Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions. CNS Spectr. 2022;27:570\u201387. https:\/\/doi.org\/10.1017\/S1092852921000523.","journal-title":"CNS Spectr"},{"key":"1338_CR9","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jama.2009.1549","volume":"302","author":"CU Correll","year":"2009","unstructured":"Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765\u201373. https:\/\/doi.org\/10.1001\/jama.2009.1549.","journal-title":"JAMA"},{"key":"1338_CR10","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1586\/ern.10.85","volume":"10","author":"L Maayan","year":"2010","unstructured":"Maayan L, Correll CU. Management of antipsychotic-related weight gain. Expert Rev Neurother. 2010;10:1175\u2013200. https:\/\/doi.org\/10.1586\/ern.10.85.","journal-title":"Expert Rev Neurother"},{"key":"1338_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/wps.20765","volume":"19","author":"M Solmi","year":"2020","unstructured":"Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020;19:214\u201332. https:\/\/doi.org\/10.1002\/wps.20765.","journal-title":"World Psychiatry"},{"key":"1338_CR12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/S2352-4642(24)00098-1","volume":"8","author":"M Rogdaki","year":"2024","unstructured":"Rogdaki M, McCutcheon RA, D\u2019Ambrosio E, Mancini V, Watson CJ, Fanshawe JB, et al. Comparative physiological effects of antipsychotic drugs in children and young people: a network meta-analysis. Lancet Child Adolesc Health. 2024;8:510\u201321. https:\/\/doi.org\/10.1016\/S2352-4642(24)00098-1.","journal-title":"Lancet Child Adolesc Health."},{"key":"1338_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2025.174012","volume":"251","author":"SF Collares","year":"2025","unstructured":"Collares SF, de \u00c1vila J\u00fanior AM, Martins TC, Rezende VHM, Romano-Silva MA, Santos RMS, et al. Systematic review and meta-analysis of weight gain and metabolic changes in children and adolescents using second-generation antipsychotics. Pharmacol Biochem Behav. 2025;251:174012. https:\/\/doi.org\/10.1016\/j.pbb.2025.174012.","journal-title":"Pharmacol Biochem Behav"},{"key":"1338_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/wps.21279","volume":"24","author":"M H\u00f8jlund","year":"2025","unstructured":"H\u00f8jlund M, Wesselhoeft R, Heinrichsen M, Pagsberg AK, Correll CU, Steinhausen H-C. Excess cardiometabolic risk in children and adolescents initiating antipsychotic treatment compared to young adults: results from a nationwide cohort study. World Psychiatry. 2025;24:103\u201312. https:\/\/doi.org\/10.1002\/wps.21279.","journal-title":"World Psychiatry"},{"key":"1338_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bcpt.13711","volume":"130","author":"M H\u00f8jlund","year":"2022","unstructured":"H\u00f8jlund M, Wagner CB, Wesselhoeft R, Andersen K, Fink-Jensen A, Hallas J. Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: a nation-wide cohort study. Basic Clin Pharmacol Toxicol. 2022;130:501\u201312. https:\/\/doi.org\/10.1111\/bcpt.13711.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1338_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/wps.20309","volume":"15","author":"D Vancampfort","year":"2016","unstructured":"Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15:166\u201374. https:\/\/doi.org\/10.1002\/wps.20309.","journal-title":"World Psychiatry"},{"key":"1338_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/wps.20252","volume":"14","author":"D Vancampfort","year":"2015","unstructured":"Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339\u201347. https:\/\/doi.org\/10.1002\/wps.20252.","journal-title":"World Psychiatry"},{"key":"1338_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamapsychiatry.2015.2923","volume":"73","author":"B Galling","year":"2016","unstructured":"Galling B, Rold\u00e1n A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiat. 2016;73:247\u201359. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.2923.","journal-title":"JAMA Psychiat"},{"key":"1338_CR19","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1007\/s00787-025-02771-0","volume":"34","author":"RP Radha Krishnan","year":"2025","unstructured":"Radha Krishnan RP, Dzidowska M, Zheng D, Wong ZS-Y, Buckley NA, Raubenheimer JE. Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence. Eur Child Adolesc Psychiatry. 2025;34:3331\u201343. https:\/\/doi.org\/10.1007\/s00787-025-02771-0.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1338_CR20","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United States. JAMA Psychiat. 2015;72:867. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0500.","journal-title":"JAMA Psychiat"},{"key":"1338_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2215-0366(22)00404-7","volume":"10","author":"MR Radoj\u010di\u0107","year":"2000","unstructured":"Radoj\u010di\u0107 MR, Pierce M, Hope H, Senior M, Taxiarchi VP, Trefan L, et al. Trends in antipsychotic prescribing to children and adolescents in England: cohort study using 2000\u201319 primary care data. Lancet Psychiatry. 2000;10:119\u201328. https:\/\/doi.org\/10.1016\/S2215-0366(22)00404-7.","journal-title":"Lancet Psychiatry"},{"key":"1338_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4088\/JCP.15r10435","volume":"78","author":"C Cervesi","year":"2017","unstructured":"Cervesi C, Park SY, Galling B, Molteni S, Masi G, Gerhard T, et al. Extent, time course, and moderators of antipsychotic treatment in youth with mood disorders: results of a meta-analysis and meta-regression analyses. J Clin Psychiatry. 2017;78:347\u201357. https:\/\/doi.org\/10.4088\/JCP.15r10435.","journal-title":"J Clin Psychiatry"},{"key":"1338_CR23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jaac.2016.03.012","volume":"55","author":"SY Park","year":"2016","unstructured":"Park SY, Cervesi C, Galling B, Molteni S, Walyzada F, Ameis SH, et al. Antipsychotic use trends in youth with autism spectrum disorder and\/or intellectual disability: a meta-analysis. J Am Acad Child Adolesc Psychiatry. 2016;55:456-468.e4. https:\/\/doi.org\/10.1016\/j.jaac.2016.03.012.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1338_CR24","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1007\/s10578-022-01330-x","volume":"54","author":"S Nakane","year":"2023","unstructured":"Nakane S, Tanaka-Mizuno S, Nishiyama C, Kochi K, Yamamoto-Sasaki M, Takeuchi M, et al. Trends in prescribing antipsychotics for children and adolescents in Japan: a descriptive epidemiological study using a large-scale pharmacy dataset. Child Psychiatry Hum Dev. 2023;54:1250\u20137. https:\/\/doi.org\/10.1007\/s10578-022-01330-x.","journal-title":"Child Psychiatry Hum Dev"},{"key":"1338_CR25","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1001\/jamapsychiatry.2015.0632","volume":"72","author":"CU Correll","year":"2015","unstructured":"Correll CU, Blader JC. Antipsychotic use in youth without psychosis: a double-edged sword. JAMA Psychiat. 2015;72:859. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0632.","journal-title":"JAMA Psychiat"},{"key":"1338_CR26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jadohealth.2020.06.039","volume":"68","author":"TM Jensen","year":"2021","unstructured":"Jensen TM, Duke NN, Harris KM, Hotz VJ, Perreira KM. Like parent, like child: intergenerational patterns of cardiovascular risk factors at midlife. J Adolesc Health. 2021;68:596\u2013603. https:\/\/doi.org\/10.1016\/j.jadohealth.2020.06.039.","journal-title":"J Adolesc Health"},{"key":"1338_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244826","volume":"15","author":"C Eberle","year":"2020","unstructured":"Eberle C, Kirchner MF, Herden R, Stichling S. Paternal metabolic and cardiovascular programming of their offspring: a systematic scoping review. PLoS ONE. 2020;15:e0244826. https:\/\/doi.org\/10.1371\/journal.pone.0244826.","journal-title":"PLoS ONE"},{"key":"1338_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamapsychiatry.2015.0346","volume":"72","author":"E Agerbo","year":"2015","unstructured":"Agerbo E, Sullivan PF, Vilhj\u00e1lmsson BJ, Pedersen CB, Mors O, B\u00f8rglum AD, et al. Polygenic risk score, parental socioeconomic status, family history of psychiatric disorders, and the risk for schizophrenia: a Danish population-based study and meta-analysis. JAMA Psychiat. 2015;72:635\u201341. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0346.","journal-title":"JAMA Psychiat"},{"key":"1338_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/jamapsychiatry.2020.4172","volume":"78","author":"E Agerbo","year":"2021","unstructured":"Agerbo E, Trabjerg BB, B\u00f8rglum AD, Schork AJ, Vilhj\u00e1lmsson BJ, Pedersen CB, et al. Risk of early-onset depression associated with polygenic liability, parental psychiatric history, and socioeconomic status. JAMA Psychiat. 2021;78:387\u201397. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.4172.","journal-title":"JAMA Psychiat"},{"key":"1338_CR30","doi-asserted-by":"publisher","first-page":"e2451837","DOI":"10.1001\/jamanetworkopen.2024.51837","volume":"7","author":"P Wang","year":"2024","unstructured":"Wang P, Gao X, Willett WC, Giovannucci EL. Socioeconomic status, diet, and behavioral factors and cardiometabolic diseases and mortality. JAMA Netw Open. 2024;7:e2451837. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.51837.","journal-title":"JAMA Netw Open"},{"key":"1338_CR31","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.dsx.2019.04.003","volume":"13","author":"M Blanquet","year":"2019","unstructured":"Blanquet M, Legrand A, P\u00e9lissier A, Mourgues C. Socio-economics status and metabolic syndrome: a meta-analysis. Diabetes Metab Syndr. 2019;13:1805\u201312. https:\/\/doi.org\/10.1016\/j.dsx.2019.04.003.","journal-title":"Diabetes Metab Syndr"},{"key":"1338_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12933-023-02017-w","volume":"22","author":"RD Triatin","year":"2023","unstructured":"Triatin RD, Chen Z, Ani A, Wang R, Hartman CA, Nolte IM, et al. Familial co-aggregation and shared genetics of cardiometabolic disorders and traits: data from the multi-generational Lifelines Cohort Study. Cardiovasc Diabetol. 2023;22:282. https:\/\/doi.org\/10.1186\/s12933-023-02017-w.","journal-title":"Cardiovasc Diabetol"},{"key":"1338_CR33","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s00125-011-2267-5","volume":"54","author":"P Almgren","year":"2011","unstructured":"Almgren P, Lehtovirta M, Isomaa B, Sarelin L, Taskinen MR, Lyssenko V, et al. Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study. Diabetologia. 2011;54:2811\u20139. https:\/\/doi.org\/10.1007\/s00125-011-2267-5.","journal-title":"Diabetologia"},{"key":"1338_CR34","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ng.2797","volume":"45","author":"CJ Willer","year":"2013","unstructured":"Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274\u201383. https:\/\/doi.org\/10.1038\/ng.2797.","journal-title":"Nat Genet"},{"key":"1338_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fendo.2012.00029","volume":"3","author":"CE Elks","year":"2012","unstructured":"Elks CE, den Hoed M, Zhao JH, Sharp SJ, Wareham NJ, Loos RJF, et al. Variability in the heritability of body mass index: a systematic review and meta-regression. Front Endocrinol (Lausanne). 2012;3:29. https:\/\/doi.org\/10.3389\/fendo.2012.00029.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"1338_CR36","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1093\/schbul\/sbw058","volume":"42","author":"J-P Zhang","year":"2016","unstructured":"Zhang J-P, Lencz T, Zhang RX, Nitta M, Maayan L, John M, et al. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull. 2016;42:1418\u201337. https:\/\/doi.org\/10.1093\/schbul\/sbw058.","journal-title":"Schizophr Bull"},{"key":"1338_CR37","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X.","journal-title":"Lancet"},{"key":"1338_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1403494811401482","volume":"39","author":"E Lynge","year":"2011","unstructured":"Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39:30\u20133. https:\/\/doi.org\/10.1177\/1403494811401482.","journal-title":"Scand J Public Health"},{"key":"1338_CR39","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/ije\/dyw213","volume":"46","author":"A Potteg\u00e5rd","year":"2017","unstructured":"Potteg\u00e5rd A, Schmidt SAJ, Wallach-Kildemoes H, S\u00f8rensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46:798\u2013798f. https:\/\/doi.org\/10.1093\/ije\/dyw213.","journal-title":"Int J Epidemiol"},{"key":"1338_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12911-015-0140-z","volume":"15","author":"A Tanskanen","year":"2015","unstructured":"Tanskanen A, Taipale H, Koponen M, Tolppanen A-M, Hartikainen S, Ahonen R, et al. From prescription drug purchases to drug use periods\u2014a second generation method (PRE2DUP). BMC Med Inform Decis Mak. 2015;15:21. https:\/\/doi.org\/10.1186\/s12911-015-0140-z.","journal-title":"BMC Med Inform Decis Mak"},{"key":"1338_CR41","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","volume":"20","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512\u201322. https:\/\/doi.org\/10.1097\/EDE.0b013e3181a663cc.","journal-title":"Epidemiology"},{"key":"1338_CR42","doi-asserted-by":"publisher","unstructured":"International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103\u20139. https:\/\/doi.org\/10.1038\/nature10405.","DOI":"10.1038\/nature10405"},{"key":"1338_CR43","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S0140-6736(16)32380-7","volume":"389","author":"S Stringhini","year":"2017","unstructured":"Stringhini S, Carmeli C, Jokela M, Avenda\u00f1o M, Muennig P, Guida F, et al. Socioeconomic status and the 25 \u00d7 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1\u00b77 million men and women. Lancet. 2017;389:1229\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(16)32380-7.","journal-title":"Lancet"},{"key":"1338_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1377\/hlthaff.21.2.60","volume":"21","author":"NE Adler","year":"2002","unstructured":"Adler NE, Newman K. Socioeconomic disparities in health: pathways and policies. Health Aff (Millwood). 2002;21:60\u201376. https:\/\/doi.org\/10.1377\/hlthaff.21.2.60.","journal-title":"Health Aff (Millwood)"},{"key":"1338_CR45","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1056\/NEJMoa072515","volume":"357","author":"JL Baker","year":"2007","unstructured":"Baker JL, Olsen LW, S\u00f8rensen TIA. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med. 2007;357:2329\u201337. https:\/\/doi.org\/10.1056\/NEJMoa072515.","journal-title":"N Engl J Med"},{"key":"1338_CR46","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1056\/NEJMoa1006992","volume":"364","author":"A Tirosh","year":"2011","unstructured":"Tirosh A, Shai I, Afek A, Dubnov-Raz G, Ayalon N, Gordon B, et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med. 2011;364:1315\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1006992.","journal-title":"N Engl J Med"},{"key":"1338_CR47","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/diacare.27.2.596","volume":"27","author":"American Diabetes Association","year":"2004","unstructured":"American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596\u2013601. https:\/\/doi.org\/10.2337\/diacare.27.2.596.","journal-title":"Diabetes Care"},{"key":"1338_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1017\/S003329171100105X","volume":"42","author":"AJ Mitchell","year":"2012","unstructured":"Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42:125\u201347. https:\/\/doi.org\/10.1017\/S003329171100105X.","journal-title":"Psychol Med"},{"key":"1338_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/JCP.0000000000001322","volume":"41","author":"M Dinnissen","year":"2021","unstructured":"Dinnissen M, Dietrich A, van der Molen JH, Verhallen AM, Buiteveld Y, Jongejan S, et al. Guideline adherence of monitoring antipsychotic use for nonpsychotic indications in children and adolescents: a patient record review. J Clin Psychopharmacol. 2021;41:13\u20138. https:\/\/doi.org\/10.1097\/JCP.0000000000001322.","journal-title":"J Clin Psychopharmacol"},{"key":"1338_CR50","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1097\/MJT.0000000000000853","volume":"27","author":"S Wakefield","year":"2020","unstructured":"Wakefield S, Aligeti M, Rachamallu V, Baronia R, Aynampudi R, Parmar A, et al. Metabolic monitoring of child and adolescent patients on atypical antipsychotics by psychiatrists and primary care providers. Am J Ther. 2020;27:e425\u201330. https:\/\/doi.org\/10.1097\/MJT.0000000000000853.","journal-title":"Am J Ther"},{"key":"1338_CR51","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jamapsychiatry.2025.2536","volume":"82","author":"M Zierhut","year":"2025","unstructured":"Zierhut M, Weiser M, Thanarajah SE, Opel N. GLP-1 receptor agonists for pharmacologically induced weight gain. JAMA Psychiat. 2025;82:1063\u20134. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.2536.","journal-title":"JAMA Psychiat"},{"key":"1338_CR52","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1176\/ajp.2006.163.12.2072","volume":"163","author":"DJ Klein","year":"2006","unstructured":"Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163:2072\u20139. https:\/\/doi.org\/10.1176\/ajp.2006.163.12.2072.","journal-title":"Am J Psychiatry"},{"key":"1338_CR53","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamapsychiatry.2016.1232","volume":"73","author":"E Anagnostou","year":"2016","unstructured":"Anagnostou E, Aman M, Handen B, Sanders K, Shui A, Hollway J, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial. JAMA Psychiat. 2016;73:928\u201337. https:\/\/doi.org\/10.1001\/jamapsychiatry.2016.1232.","journal-title":"JAMA Psychiat"},{"key":"1338_CR54","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.2332","author":"AA Ganeshalingam","year":"2025","unstructured":"Ganeshalingam AA, Uhrenholt N, Arnfred S, G\u00e6de P, D\u00fcring S, Stenager EN, et al. Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial. JAMA Psychiat. 2025. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.2332.","journal-title":"JAMA Psychiat"},{"key":"1338_CR55","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S2215-0366(25)00129-4","volume":"12","author":"D Siskind","year":"2025","unstructured":"Siskind D, Baker A, Arnautovska U, Warren N, Russell A, DeMonte V, et al. Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator-blinded, randomised controlled trial in Australia. Lancet Psychiatry. 2025;12:493\u2013503. https:\/\/doi.org\/10.1016\/S2215-0366(25)00129-4.","journal-title":"Lancet Psychiatry"},{"key":"1338_CR56","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber D, Barrett T, Barrientos-P\u00e9rez M, Gies I, Hesse D, Jeppesen OK, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387:2245\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2208601.","journal-title":"N Engl J Med"},{"key":"1338_CR57","unstructured":"Early Psychosis Intervention Ontario Network. Metabolic monitoring interactive tool. https:\/\/epiontario.org\/early-psychosis-intervention-ontario-network-epion-metabolic-monitoring-interactive-tool\/. Accessed 4 Oct 2025."},{"key":"1338_CR58","unstructured":"American Psychiatric Association. Lifestyle to support mental health. https:\/\/www.psychiatry.org\/patients-families\/lifestyle-to-support-mental-health. Accessed 4 Oct 2025."},{"key":"1338_CR59","unstructured":"National Institutes of Health. Physical wellness toolkit. 2025. https:\/\/www.nih.gov\/health-information\/your-healthiest-self-wellness-toolkits\/physical-wellness-toolkit. Accessed 4 Oct 2025."},{"key":"1338_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2021.100175","volume":"6","author":"SF Katz","year":"2021","unstructured":"Katz SF, Rodriguez F, Knowles JW. Health disparities in cardiometabolic risk among Black and Hispanic youth in the United States. Am J Prev Cardiol. 2021;6:100175. https:\/\/doi.org\/10.1016\/j.ajpc.2021.100175.","journal-title":"Am J Prev Cardiol."},{"key":"1338_CR61","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64\u201377. https:\/\/doi.org\/10.1016\/S2215-0366(19)30416-X.","journal-title":"Lancet Psychiatry"},{"key":"1338_CR62","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/wps.21036","volume":"22","author":"A Burschinski","year":"2023","unstructured":"Burschinski A, Schneider-Thoma J, Chiocchia V, Schestag K, Wang D, Siafis S, et al. Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials. World Psychiatry. 2023;22:116\u201328. https:\/\/doi.org\/10.1002\/wps.21036.","journal-title":"World Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01338-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01338-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01338-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:02:46Z","timestamp":1791676966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01338-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":62,"alternative-id":["1338"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01338-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MH received honoraria for lectures from\/has been a consultant for Lundbeck, Orion, Otsuka, and Rovi. CUC has been a consultant and\/or advisor to or has received honoraria from: AbbVie, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Bristol-Myers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen\/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He provided expert testimony for Janssen, Lundbeck and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva, Rovi. He has received grant support from Boehringer-Ingelheim, Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, and Terran. HCS received royalties from Elsevier, Cambridge University Press, Hogrefe, and Kohlhammer publishers. AKP and RW declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of de-identified data for this study was approved by the Capital Region of Denmark (P-2022-307) and Statistics Denmark (706672). Under Danish law, register-based studies of de-identified data do not require approval from a health research ethics committee or informed consent.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data were obtained from Statistics Denmark and cannot be shared publicly due to Danish data protection regulations. Access to the data is available to approved researchers through secure servers at Statistics Denmark upon application and institutional approval. The use of de-identified data for this project was approved by the Capital Region of Denmark (P-2022-307) and Statistics Denmark (706672).","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Stata code used for the analyses is available from the corresponding author on reasonable request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Concept and design: Steinhausen, H\u00f8jlund, Correll. Acquisition, analysis, or interpretation of data: All authors. Drafting the manuscript: H\u00f8jlund, Wesselhoeft. Critical review of the manuscript for important intellectual content: All authors. Statistical analysis: H\u00f8jlund. Obtained funding: Steinhausen, Pagsberg, Correll. Administrative, technical, or material support: Pagsberg. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}